Dallas, Texas (PRWEB) September 29, 2013
A biomarker is an identifiable and measurable characteristic, which identifies the severity and/or occurrence of a specific disease. It has major applications in the discovery and development of novel therapeutic drugs. The global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. It is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.
Advancements in discovery technologies, high demand from the indications of various diseases, increasing partnerships and collaborations to boost biomarker research activities, increase in government and private sector investments and funds for biomarker discovery, FDA support for biomarker development, and increasing utility of biomarkers in patient stratification and drug development process are the major drivers slated to propel the growth of this market. However, a few pivotal factors such as the high capital investment and low benefit-cost ratio, cumbersome biomarker validation procedure, and difficulty in sample collection and its storage are expected to hamper the growth of this market.
The global market has been segmented into discovery technologies, services, applications, and disease indications. The biomarker discovery technology market has been further segmented into omics technology, imaging technology, and bioinformatics. The omics technology segment accounts for the largest share in this market, primarily due to the increase in adoption of proteomics and genomics technologies across the globe.
In addition, the biomarker services (sample preparation, assay development, and biomarker validation and testing) and applications (drug discovery and formulation, and development of molecular diagnostics and personalized medicine) market have also been illustrated in the report. Drug discovery and development segment holds the largest share of biomarker applications market. This is attributed to the potential of biomarkers to reduce the time span of clinical trials, which ultimately decreases the overall cost of the entire drug discovery and development process.
On the basis of type of disease, the global biomarkers market is further classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis). Oncology biomarkers market accounts for the lion’s share of the biomarker disease indication market and further this market is forecast to grow at the highest growth rate in the next five years. Increasing need for the early diagnosis of tumor cells is the major factor stimulating the growth of oncology market. Oncology biomarkers enhance the screening and early detection of cancer as well as facilitate the high-speed, non-invasive cancer diagnosis procedure.
The key players in this market are Roche Diagnostics Limited (Switzerland), Johnson & Johnson (U.S.), GlaxoSmithKline, Plc. (U.K.), Siemens Healthcare (Germany), Abbott Laboratories, Inc. (U.S.), GE Healthcare (U.K.), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Epigenomics AG (Germany), Eisai Co. Ltd. (Japan), Bio-Rad Laboratories, Inc. (U.S.), Eli Lilly and Company (U.S.), Merck & Co. (U.S.), Genomic Health, Inc. (U.S.), and Agilent Technologies Inc. (U.S.)
Scope of the Report
This research report categorizes the global biomarkers market on the basis of discovery technology, services, applications, and disease indications. These markets are broken down into segments and sub-segments, providing value analysis for 2011, 2012, and 2013 as well as forecast up to 2018. Each market is comprehensively analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World), to provide in-depth information on the global scenario.
Majors points of table of content
10 Company Profiles
10.1 Abbott Laboratories
10.2 Abcodia Ltd
10.3 Affymetrix Inc
10.4 Agilent Technologies Inc
10.5 Amgen Inc
10.6 Astrazeneca Plc
10.7 Augurex Life Sciences Corp
10.8 Aushon Biosystems Inc
10.9 Bayer Ag
10.12 Biocrates Life Sciences Ag
10.13 Biomarkers Strategies
10.14 Biosystems International
10.15 Bristol-Myers Squibb
10.16 Crescendo Bioscience
10.17 Eisai Co. Ltd.
10.18 Epiontis Gmbh
10.19 Epistem Holdings Plc
10.20 Eurogentec S.A.
10.21 Evotec Ag
10.22 Glaxosmithkline Plc etc.
Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=60026 .
Browse more reports on Information Technology & Telecommunication Market @ http://www.rnrmarketresearch.com/reports/information-technology-telecommunication .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Explore industry research reports focused on China at http://chinamarketresearchreports.com/ .
Read the full story at http://www.prweb.com/releases/2018-biomarkers-market/analysis-and-forecast/prweb11170675.htm.
Copyright©2012 Vocus, Inc.
All rights reserved